A40 IBD PATIENTS RECEIVING INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR ARE LESS LIKELY TO DEVELOP SECONDARY LOSS OF RESPONSE

BACKGROUND: Anti-TNF therapy is well established in the treatment of moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). Therapeutic effect may wane over time leading to secondary loss of response that can be overcome with dose escalation. Data on rate of secondary loss of response...

Full description

Saved in:
Bibliographic Details
Published in:J Can Assoc Gastroenterol
Main Authors: Elias, E, Oketola, A, Krishnan, S, Singh, H, Targownik, L, Bernstein, C N
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Posters Of Distinction
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512547/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.039
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items